Home » Market News » DirectorsTalk Highlights » Vaccine against COVID-19
Open Orphan PLC

Vaccine against COVID-19

Research on vaccines against the novel coronavirus (SARS-CoV-2) is being carried out all over the world. If a vaccine becomes available in the future, the Ministry of Health, Welfare and Sport will ask the Health Council of the Netherlands and RIVM National Institute for Public Health and the Environment   for advice on choosing the vaccine that will be used in the Netherlands. RIVM coordinates the control of infectious diseases in the Netherlands. 

Developing a vaccine is a long-term process

It is difficult to say when there will be an effective vaccine against the novel coronavirus.  It takes a long time to develop a vaccine for a new infectious disease, usually as long as 5 to 10 years. Every effort is being made to accelerate development of a vaccine for COVID-19. However, before a well-functioning vaccine can be developed, a substantial amount of research has to be done on the virus itself. In addition, the possible vaccine also needs to be clinically tested in humans for safety and efficacy. All this takes a lot of time. 

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.